Luan and colleagues 1 provide evidence that increasing the duration of CMV prophylaxis to 6 months in seronegative kidney and/or pancreas transplant recipients who receive transplants from ...

Prophylactic oral ganciclovir therapy reduces the incidence of CMV disease in kidney and liver transplant recipients. It is more effective for recipients who are seronegative before the transplant ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection, usually in a latent form in various tissues (e.g., kidney, liver, lung). [1] One percent of ...

We wanted to find out if pre-emptive treatment aimed at transplant recipients who are at risk of developing CMV disease, rather than administering universal prophylaxis, including those who are ...

CMV is one of the most common and serious post-transplant infections with an estimated incidence rate of between 16% and 56% in solid organ transplants, and 30% to 70% in HSCT procedures.

More than 55% of transplant recipients with refractory CMV infections achieved confirmed viral clearance with Takeda's drug, compared to around 24% of those on conventional antivirals.